Shenzhen Kangtai Partners with AstraZeneca to Establish Vaccine JV in Beijing
China-based Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601) has formed a vaccine-focused partnership with...
Company
Syneron Bio Collaborates with AstraZeneca to Develop Macrocyclic Peptides for Chronic Diseases
China-based Syneron Bio, a biotech firm specializing in macrocyclic peptide drugs, has entered into a...
Hainan Poly Pharm Faces Delisting After CSRC Imposes Strict Penalties for Financial Misconduct
China-based Hainan Poly Pharm Co., Ltd (SHE: 300630) was imposed strict administrative penalties by the...
AstraZeneca Unveils USD2.5 Billion Beijing R&D Center Plan Amid Strategic China Partnerships
UK-based pharmaceutical giant AstraZeneca (NASDAQ: AZN) has announced a five-year plan to invest USD 2.5...
Innovent Biologics Doses First Patient with IBI354 in HeriCare-Ovarian01 Study
China-based Innovent Biologics, Inc. (HKG: 1801) has administered the first dose of its antibody-drug conjugate...
Everest Medicines’ EVM14 mRNA Cancer Vaccine Clears US FDA IND Application
China-based Everest Medicines (HKG: 1952) has announced that its Investigational New Drug (IND) application for...
Harbour BioMed Partners with AstraZeneca on Multi-Specific Antibody Development
China-based Harbour BioMed (HKG: 2142) has formed a strategic partnership with UK pharmaceutical giant AstraZeneca...
CSPC Pharmaceutical Group Gains NMPA Approval for SYS6040 Clinical Trial
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced receiving approval from the National Medical...
Duality Biotherapeutics Clears HKEX Hearing, Set for IPO with $2.7B Valuation
Duality Biotherapeutics, Inc., a biopharmaceutical company focused on developing innovative antibody-drug conjugates (ADCs), has successfully...
China Biopharmaceutical Leads AI Integration with DeepSeek-R1
Since the beginning of the year, China’s self-developed AI assistant DeepSeek has made a significant...
GE Healthcare Unveils Invenia ABUS Premium for Enhanced Dense Breast Screening
US medical device and life sciences giant GE Healthcare Technologies Inc. (NASDAQ: GEHC) has announced...
Daiichi Sankyo Launches Datroway in Japan for HR Positive, HER2 Negative Breast Cancer
Japan-based Daiichi Sankyo (TYO: 4568) has announced the launch of Datroway (datopotamab deruxtecan) in Japan....
Porton Pharma Solutions’ Porton Advanced Partners with Eureka Therapeutics on T-Cell Therapies
China-based Contract Development and Manufacturing Organization (CDMO) Porton Pharma Solutions’ subsidiary Porton Advanced, a specialist...
Triastek’s 3D-Printed T20G Receives US Clinical Approval for NOAC Treatment
China-based Triastek Inc., a pharmaceutical-focused 3D printing company, has announced receiving clinical approval in the...
Johnson & Johnson’s Tremfya Gains FDA Approval for Crohn’s Disease Treatment
US pharmaceutical giant Johnson & Johnson (J&J, NYSE: JNJ) has announced receiving clearance from the...
Menarini Group Partners with VisualDx to Enhance BPDCN Identification Using AI/ML Tools
Italy’s Menarini Group, through its subsidiary Stemline Therapeutics Inc., has formed a partnership with US-based...
Elevation Oncology Halts EO-3021 Development After Poor Phase 1 Data
US-based Elevation Oncology, Inc. (NASDAQ: ELEV) has announced the decision to terminate development of EO-3021...
Changchun High & New Technology Industries Receives US Trial Approval for GenSci120 in Rheumatoid Arthritis
China-based Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced its subsidiary GenScipt...
Novartis’ Fabhalta Approved by FDA for C3 Glomerulopathy Treatment
Swiss pharmaceutical giant Novartis’ (NYSE: NVS) iptacopan, marketed as Fabhalta, has received approval from the...
Sino Biopharmaceutical’s 2024 Revenue Up 10.2% on Strong Innovative Drug Sales
China-based Sino Biopharmaceutical Ltd (HKG: 1177) released its 2024 financial report, recording revenues of RMB...